Connect with us

Hi, what are you looking for?


This biotech stock could double from here: Goldman Sachs

Vir Biotechnology Inc (NASDAQ: VIR) jumped nearly 10% this morning after a Goldman Sachs analyst turned super bullish on the clinical-stage immunology company.

Vir stock has upside to $53 a share

On Tuesday, Paul Choi upgraded the biotech stock to “buy” and raised his price target significantly to $53 that represents about a 100% upside from here.

The bullish call is based primarily on VIR-2482 – the company’s new, more potent vaccine for flu. His research note reads:

VIR will report VIR-2482 data in mid-2023, which we expect to show meaningfully better efficacy than currently approved and rival pipeline-stage flu vaccines and drive material upward revisions to consensus estimates.

The Goldman Sachs analyst dubbed Vir stock a compelling risk-reward now that it’s been cut in more than half over the pasts 24 months.

How is VIR-2482 different than rivals?

VIR-2482 targets the Influenza Hemagglutinin (HA) stem that would potentially help sustain its efficacy in flu season every year since the said region is highly conserved. Choi added:

While previous antibody challenge studies have failed, modifications to VIR-2482 that result in increased potency (ADCC) and a longer half-life should provide sufficient serum coverage well above EC90 over a flu season.

The Nasdaq-listed firm is expected to lose 4 cents a share this quarter – well below $3.92 per share it “earned” a year ago. It’s scheduled to report its quarterly results later this week.

But the Goldman Sachs analyst remains convinced that the new vaccine could unlock a post-COVID rally in the Vir stock in the coming months.

The post This biotech stock could double from here: Goldman Sachs appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Reprinted from the Future of Freedom Foundation President Biden’s campaign to banish (or maybe outlaw) political paranoia took a wallop last spring. In April,...


    Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...

    Editor's Pick

    It’s already a cliché, but technology is rapidly improving. And for many businesses, it’s hard to catch up. However, it’s not just the average...

    Editor's Pick

    At Broadband World Forum 2022, Fibocom launched 5G module FG370 based on MediaTek T830 platform, aiming to empower the deployment of 5G FWA for...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.